This week The American Journal of Managed Care offers a special episode of highlights from the American Society of Hematology's annual meeting, including sessions on newly approved treatments, how the move to pay-for-performance affects hematologists, and the increasing role of patient-reported outcomes.
Hello, I’m Justin Gallagher, associate publisher of The American Journal of Managed Care. Welcome to This Week in Managed Care, from the Managed Markets News Network.
This week, we bring you highlights from the American Society of Hematology’s recent meeting in Orlando, Florida.
Newly Approved Drugs
New therapies received plenty of attention, since the FDA was quite busy in the weeks leading up to ASH.
At a special session with the FDA, reviewers who handled approvals for 3 new drugs to treat multiple myeloma discussed the evidence for daratumumab, ixazomib, and elotuzumab. Then, physicians who have used the drugs in clinical practice shared their thoughts on how to sequence these new therapies and use them in combination with existing therapies, such as lenalidomide and dexamethasone, or bortezomib.
One expert at the session said there are now 22 potential treatment strategies for multiple myeloma within the NCCN guidelines.
At a separate session on newly approved treatments, a presentation on blinatumomab, which has been approved for acute lymphoblastic leukemia, showed that while administering the drug presents some challenges, it’s also meeting an unmet need for certain patients.
Scientists from the University of Utah presented findings that show that rivaroxaban could be an alternative to low-molecular weight heparin to treat venous thromboembolism in cancer patients. Among 92 cancer patients who received rivaroxaban, 10 had a major bleeds after an average period of 4 months, although other drugs may have contributed to these events. Only 4 patients had recurrent VTE while taking rivaroxaban, leading researchers to conclude that the therapy may be a safe and acceptable alternative to heparin in cancer patients.
Dr. Helen Burstin, the chief scientific officer at the National Quality Forum, explained that CMS wants 50 percent of reimbursement to be tied to value-based payment models by 2018, while Dr. Andrew Ryan of the University of Michigan wondered what the current reporting systems will mean for hematologists.
Patient reported outcomes will continue to play a bigger role, and Dr. David Cella of Northwestern University said this will make a difference in a field where measuring tumor response has been the norm. In the future, he said, creating measurements for things like fatigue and ability to function will carry more weight, in addition to overall survival.
ASH takes part in the Choosing Wisely campaign, an initiative of the ABIM Foundation to eliminate unnecessary tests and procedures that can cause patient harm and create added costs.
For 2015, ASH researched recommendations from other professional societies for items of interest to hematologists. The ASH Choosing Wisely committee highlighted the following:
You can read more about ASH 2015 in our upcoming special issue of Evidence-Based Oncology.
For everyone at the Managed Markets News Network, I’m Justin Gallagher. Thanks for joining us.